Risk Factors of the Efficacy of Hepatitis B Vaccine in Health-care Workers

Overview

Journal J Res Med Sci

Specialty General Medicine

Date 2020 Mar 17

PMID 32174987

Authors

Hassan Salehi

Marzieh Salehi

Nader Kalbasi

Maryam Salehi

Jalil Sharifian

Mohammad Mahdi Salehi

Affiliations

Soon will be listed here.

Abstract

Background: Conventional hepatitis B virus vaccination fails to achieve efficient protection in about 5%-10% of the world population. Different factors influence the immunogenicity of hepatitis B vaccine. This study aimed to evaluate these factors in health-care workers.

Materials And Methods: This was a descriptive study which was implemented among 140 of medical and dental staff working as health-care workers who were low responder after vaccination entered the study.

Results: Age (>40 years), weight (body mass index >25), immunodeficiency diseases, (primary immune deficiency and immunosuppressant drugs), diabetes mellitus, and smoking were the important factors.

Conclusion: In the high-risk group of hepatitis B disease, the risk factors of immunogenicity must be evaluated at vaccination and check titers of antibody after vaccination.

References

Young K, Gray C, Bekker L . Is obesity a risk factor for vaccine non-responsiveness?. PLoS One. 2013; 8(12):e82779. PMC: 3859613. DOI: 10.1371/journal.pone.0082779. View

Njom Nlend A, Nguwoh P, Ngounouh C, Tchidjou H, Pieme C, Otele J . HIV-Infected or -Exposed Children Exhibit Lower Immunogenicity to Hepatitis B Vaccine in Yaoundé, Cameroon: An Appeal for Revised Policies in Tropical Settings?. PLoS One. 2016; 11(9):e0161714. PMC: 5033457. DOI: 10.1371/journal.pone.0161714. View

Alimonos K, Nafziger A, Murray J, Bertino Jr J . Prediction of response to hepatitis B vaccine in health care workers: whose titers of antibody to hepatitis B surface antigen should be determined after a three-dose series, and what are the implications in terms of cost-effectiveness?. Clin Infect Dis. 1998; 26(3):566-71. DOI: 10.1086/514575. View

Schillie S, Murphy T, Sawyer M, Ly K, Hughes E, Jiles R . CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering postexposure management. MMWR Recomm Rep. 2013; 62(RR-10):1-19. View

Van Der Meeren O, Crasta P, Cheuvart B, de Ridder M . Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: An integrated analysis. Hum Vaccin Immunother. 2015; 11(7):1726-9. PMC: 4514334. DOI: 10.1080/21645515.2015.1039758. View

Estevez Z, Betancourt A, Muzio Gonzalez V, Baile N, Silva C, Bernal F . Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults. Biologicals. 2006; 35(2):115-22. DOI: 10.1016/j.biologicals.2006.06.001. View

Hullar M, Lampe J . The gut microbiome and obesity. Nestle Nutr Inst Workshop Ser. 2012; 73:67-79. DOI: 10.1159/000341288. View

Beasley L, Koster A, Newman A, Javaid M, Ferrucci L, Kritchevsky S . Inflammation and race and gender differences in computerized tomography-measured adipose depots. Obesity (Silver Spring). 2009; 17(5):1062-9. PMC: 3268118. DOI: 10.1038/oby.2008.627. View

Zaffina S, Marcellini V, Santoro A, Scarsella M, Camisa V, Vinci M . Repeated vaccinations do not improve specific immune defenses against Hepatitis B in non-responder health care workers. Vaccine. 2014; 32(51):6902-6910. DOI: 10.1016/j.vaccine.2014.10.066. View

10.

Duan Z, Chen X, Liang Z, Zeng Y, Zhu F, Long L . Genetic polymorphisms of CXCR5 and CXCL13 are associated with non-responsiveness to the hepatitis B vaccine. Vaccine. 2014; 32(41):5316-22. DOI: 10.1016/j.vaccine.2014.07.064. View

11.

Averhoff F, Mahoney F, Coleman P, Schatz G, HURWITZ E, Margolis H . Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med. 1998; 15(1):1-8. DOI: 10.1016/s0749-3797(98)00003-8. View

12.

Mast E, Weinbaum C, Fiore A, Alter M, Bell B, Finelli L . A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006; 55(RR-16):1-33. View

13.

Fabrizi F, Tarantino A, Castelnovo C, Martin P, Messa P . Recombinant Hepatitis B Vaccine Adjuvanted With AS04 in Dialysis Patients: A Prospective Cohort Study. Kidney Blood Press Res. 2015; 40(6):584-92. DOI: 10.1159/000368534. View

14.

Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M . Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation. 2002; 105(7):804-9. DOI: 10.1161/hc0702.104279. View

15.

Adkins J, Wagstaff A . Recombinant hepatitis B vaccine: a review of its immunogenicity and protective efficacy against hepatitis B. BioDrugs. 2007; 10(2):137-58. DOI: 10.2165/00063030-199810020-00005. View

16.

Chathuranga L, Noordeen F, Abeykoon A . Immune response to hepatitis B vaccine in a group of health care workers in Sri Lanka. Int J Infect Dis. 2013; 17(11):e1078-9. DOI: 10.1016/j.ijid.2013.04.009. View

17.

Turnbaugh P, Ridaura V, Faith J, Rey F, Knight R, Gordon J . The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med. 2010; 1(6):6ra14. PMC: 2894525. DOI: 10.1126/scitranslmed.3000322. View